Lee's Pharmaceutical Enters Exclusive Licensing and Supply Deal for Interferon Alpha-2b Outside Greater China

Stock News

Jul 17

Lee's Pharmaceutical (HKEX: 00950) has announced the signing of an exclusive licensing agreement with Ashlins Ocular Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company. The agreement, dated July 6, 2026, grants Ashlins the rights to develop and commercialize products containing Interferon Alpha-2b for the diagnosis, prevention, or treatment of certain human diseases in all territories outside Mainland China, Hong Kong, Macau, and Taiwan.

Ashlins, a wholly-owned subsidiary of Ashlins Pharmaceuticals Holdings, Inc., focuses on acquiring, developing, and commercializing clinically validated therapies for areas with significant unmet medical needs. Under the terms of the deal, Lee's Pharmaceutical will both license and supply the Interferon Alpha-2b active pharmaceutical ingredient to Ashlins.

Lee's Pharmaceutical will receive an upfront payment and is eligible for additional development milestone payments upon achieving specific goals. Following commercialization, the company will also be entitled to annual commercial milestone payments.

Interferon Alpha-2b is a recombinant human Type I interferon active pharmaceutical ingredient produced via recombinant DNA technology. It serves as the active substance in medicines possessing antiviral and immunomodulatory activities.

The announcement highlighted that Ashlins' leadership team possesses extensive experience in U.S. regulatory strategy, clinical development, FDA approval pathways, and commercialization efforts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1108841774"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108841774\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108841774?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 21:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108841774","market":"us","top_or_hot":-1,"title":"Lee's Pharmaceutical Enters Exclusive Licensing and Supply Deal for Interferon Alpha-2b Outside Greater China","media":"Stock News","content":"<p>Lee's Pharmaceutical (HKEX: 00950) has announced the signing of an exclusive licensing agreement with Ashlins Ocular Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company. The agreement, dated July 6, 2026, grants Ashlins the rights to develop and commercialize products containing Interferon Alpha-2b for the diagnosis, prevention, or treatment of certain human diseases in all territories outside Mainland China, Hong Kong, Macau, and Taiwan.<br><br>\nAshlins, a wholly-owned subsidiary of Ashlins Pharmaceuticals Holdings, Inc., focuses on acquiring, developing, and commercializing clinically validated therapies for areas with significant unmet medical needs. Under the terms of the deal, <b>Lee's Pharmaceutical</b> will both license and supply the Interferon Alpha-2b active pharmaceutical ingredient to Ashlins.<br><br>\n<b>Lee's Pharmaceutical</b> will receive an upfront payment and is eligible for additional development milestone payments upon achieving specific goals. Following commercialization, the company will also be entitled to annual commercial milestone payments.<br><br>\nInterferon Alpha-2b is a recombinant human Type I interferon active pharmaceutical ingredient produced via recombinant DNA technology. It serves as the active substance in medicines possessing antiviral and immunomodulatory activities.<br><br>\nThe announcement highlighted that Ashlins' leadership team possesses extensive experience in U.S. regulatory strategy, clinical development, FDA approval pathways, and commercialization efforts.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lee's Pharmaceutical Enters Exclusive Licensing and Supply Deal for Interferon Alpha-2b Outside Greater China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLee's Pharmaceutical Enters Exclusive Licensing and Supply Deal for Interferon Alpha-2b Outside Greater China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-17 21:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Lee's Pharmaceutical (HKEX: 00950) has announced the signing of an exclusive licensing agreement with Ashlins Ocular Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company. The agreement, dated July 6, 2026, grants Ashlins the rights to develop and commercialize products containing Interferon Alpha-2b for the diagnosis, prevention, or treatment of certain human diseases in all territories outside Mainland China, Hong Kong, Macau, and Taiwan.<br><br>\nAshlins, a wholly-owned subsidiary of Ashlins Pharmaceuticals Holdings, Inc., focuses on acquiring, developing, and commercializing clinically validated therapies for areas with significant unmet medical needs. Under the terms of the deal, <b>Lee's Pharmaceutical</b> will both license and supply the Interferon Alpha-2b active pharmaceutical ingredient to Ashlins.<br><br>\n<b>Lee's Pharmaceutical</b> will receive an upfront payment and is eligible for additional development milestone payments upon achieving specific goals. Following commercialization, the company will also be entitled to annual commercial milestone payments.<br><br>\nInterferon Alpha-2b is a recombinant human Type I interferon active pharmaceutical ingredient produced via recombinant DNA technology. It serves as the active substance in medicines possessing antiviral and immunomodulatory activities.<br><br>\nThe announcement highlighted that Ashlins' leadership team possesses extensive experience in U.S. regulatory strategy, clinical development, FDA approval pathways, and commercialization efforts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1108841774","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108841774","pubTimestamp":1784295664,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Lee's Pharmaceutical (HKEX: 00950) has announced the signing of an exclusive licensing agreement with Ashlins Ocular Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company. The agreement,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1587":"次新股","06622":"兆科眼科-B","BK1574":"生物医药B类股","00950":"李氏大药厂","BK1583":"高瓴概念"},"translate_title":"李氏制药在大中华区以外签订干扰素α-2b独家许可和供应协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":1,"00950":1},"content_text":"Lee's Pharmaceutical (HKEX: 00950) has announced the signing of an exclusive licensing agreement with Ashlins Ocular Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company. The agreement, dated July 6, 2026, grants Ashlins the rights to develop and commercialize products containing Interferon Alpha-2b for the diagnosis, prevention, or treatment of certain human diseases in all territories outside Mainland China, Hong Kong, Macau, and Taiwan.\nAshlins, a wholly-owned subsidiary of Ashlins Pharmaceuticals Holdings, Inc., focuses on acquiring, developing, and commercializing clinically validated therapies for areas with significant unmet medical needs. Under the terms of the deal, Lee's Pharmaceutical will both license and supply the Interferon Alpha-2b active pharmaceutical ingredient to Ashlins.\nLee's Pharmaceutical will receive an upfront payment and is eligible for additional development milestone payments upon achieving specific goals. Following commercialization, the company will also be entitled to annual commercial milestone payments.\nInterferon Alpha-2b is a recombinant human Type I interferon active pharmaceutical ingredient produced via recombinant DNA technology. It serves as the active substance in medicines possessing antiviral and immunomodulatory activities.\nThe announcement highlighted that Ashlins' leadership team possesses extensive experience in U.S. regulatory strategy, clinical development, FDA approval pathways, and commercialization efforts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}